newsfilter
← Latest News
PR Newswire·

UCB Announces Global Partnership To Bring Disease-Modifying Therapies To People Living With Parkinson's Disease

BRUSSELS, Dec. 2, 2021 /PRNewswire/ -- UCB today announced that it has entered into a global co-development and co-commercialization agreement with Novartis covering UCB0599, a potential first in class, small molecule, alpha-synuclein misfolding inhibito